Pharmacovigilance Challenges in Biosimilars

This session of the Biosimilars will investigate the future and FDA activities that have just been declared to incorporate upgraded following and follow-up of post promoting observation issues, arranged enhancements in AERS, and pilots of new post market drug-monitoring strategies and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmaco epidemiology are the focuses that will be laid emphasis  in this session. U.S. normal yearly spending development from 2002 to 2007 was 16% for biologics, contrasted and 3.7% for drugs. In same extent pharmacovigilance for biosimilars has been nearly more than other pharmaceutical items

    Related Conference of Pharmacovigilance Challenges in Biosimilars

    June 13-14, 2024

    30th Asia Pacific Biotechnology Congress

    Dubai, UAE
    July 11-12, 2024

    6th International Conference on Biochemistry

    Paris, France
    September 25-26, 2024

    20th World Congress on Structural Biology

    Paris, France
    October 03-04, 2024

    15th International Conference on Biofuels and Bioenergy

    Singapore City, Singapore
    December 12-13, 2024

    15th World Congress on Cell & Tissue Science

    Rome, Italy

    Pharmacovigilance Challenges in Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in